Abstract: The present invention relates to progesterone receptor antagonists of general formula I: in which R1 can be a hydrogen atom and R2 a hydroxyl group or R1 and R2 together can be an oxo group.

Abstract: The present invention relates to progesterone receptor antagonists of general formula I: in which R1 can be a hydrogen atom and R2 a hydroxyl group or R1 and R2 together can be an oxo group.

Abstract: The present invention relates to treatment regimes and combination products of 20,20,21,21,21-pentafluoro-17-hydroxy-11?-[4-(hydroxyacetyl)phenyl]-19-nor-17?-pregna-4,9-dien-3-one of the formula This invention relates in particular to sequential regimes for the treatment of gynaecological disorders in which the abovementioned progesterone antagonist is administered in a first phase, and a progestogen is administered in a second phase.

Abstract: The present invention relates to progesterone receptor antagonists of general formula I: in which R1 can be a hydrogen atom and R2 a hydroxyl group or R1 and R2 together can be an oxo group.

Abstract: The present invention provides the use of mineralocorticoid receptor antagonists for preparing a medicament for the treatment of endometriosis. The present invention relates in particular to an improved therapeutic composition for endometriosis which has a more favorable activity and side-effect profile than treatment therapies currently available. Using a mineralocorticoid receptor antagonist, it is possible to threat endometriosis permanently without any loss of bone mass.

Abstract: The present invention relates to non-steroidal progesterone receptor modulators of the general formula I, the use of the progesterone receptor modulators for the manufacture of medicaments, and pharmaceutical compositions which comprise these compounds. The compounds according to the invention are suitable for the therapy and prophylaxis of gynecological disorders such as endometriosis, leiomyomas of the uterus, dysfunctional bleeding and dysmenorrhoea, and for the therapy and prophylaxis of hormone-dependent tumours and for use for female fertility control and for hormone replacement therapy.

Abstract: The present invention relates to non-steroidal progesterone receptor modulators of the general formula I the use of the progesterone receptor modulators for producing medicaments, and pharmaceutical compositions which comprise these compounds. The compounds according to the invention are suitable for the therapy and prophylaxis of gynaecological disorders such as endometriosis, leiomyomas of the uterus, dysfunctional bleeding and dysmenorrhoea, and for the therapy and prophylaxis of hormone-dependent tumours and for use for female fertility control and for hormone replacement therapy.

Abstract: The present invention relates to non-steroidal progesterone receptor modulators of the general formula 1, the use of the progesterone receptor modulators for the manufacture of medicaments, and pharmaceutical compositions which comprise these compounds. The compounds according to the invention are suitable for the therapy and prophylaxis of gynaecological disorders such as endometriosis, leiomyomas of the uterus, dysfunctional bleeding and dysmenorrhoea, and for the therapy and prophylaxis of hormone-dependent tumours and for use for female fertility control and for hormone replacement therapy.

Abstract: The present invention relates to progesterone receptor antagonists of general formula I: in which R1 can be a hydrogen atom and R2 a hydroxyl group or R1 and R2 together can be an oxo group.

Abstract: The present invention relates to non-steroidal progesterone receptor modulators of the general formula I, the use of the progesterone receptor modulators for the manufacture of medicaments, and pharmaceutical compositions which comprise these compounds. The compounds according to the invention are suitable for the therapy and prophylaxis of gynaecological disorders such as endometriosis, leiomyomas of the uterus, dysfunctional bleeding and dysmenorrhoea, and for the therapy and prophylaxis of hormone-dependent tumours and for use for female fertility control and for hormone replacement therapy.

Abstract: This invention relates to nonsteroidal progesterone receptor modulators of general formula I, a process for their production, the use of progesterone receptor modulators for the production of pharmaceutical agents as well as pharmaceutical compositions that contain these compounds. The compounds according to the invention are suitable for therapy and prophylaxis of gynecological diseases, such as endometriosis, leiomyomas of the uterus, dysfunctional bleeding and dysmenorrhea, as well as for the therapy and prophylaxis of hormone-dependent tumors and for use for female birth control as well as for hormone replacement therapy.

Abstract: This invention relates to nonsteroidal progesterone receptor modulators of general formula I, a process for their production, the use of progesterone receptor modulators for the production of pharmaceutical agents as well as pharmaceutical compositions that contain these compounds. The compounds according to the invention are suitable for therapy and prophylaxis of gynecological diseases, such as endometriosis, leiomyomas of the uterus, dysfunctional bleeding and dysmenorrhea, as well as for the therapy and prophylaxis of hormone-dependent tumors and for use for female birth control as well as for hormone replacement therapy.

Abstract: The present invention relates to non-steroidal progesterone receptor modulators of the general formula I, a process for their preparation, the use of the progesterone receptor modulators for producing medicaments, and pharmaceutical compositions comprising these compounds. The compounds according to the invention are suitable for the therapy and prophylaxis of gynaecological disorders such as endometriosis, leiomyomas of the uterus, dysfunctional bleeding and dysmenorrhoea, and for the therapy and prophylaxis of hormone-dependent tumours and for use for female fertility control and for hormone replacement therapy.

Abstract: The present invention relates to the use of non-steroidal progesterone receptor modulators of the general formula (I) for the therapy and prophylaxis of gynaecological disorders and of hormone-dependent tumours, and for use for female fertility control and for hormone replacement therapy.

Abstract: The invention relates to a system for pulse magnetizing high-precision magnetic scales. The system comprises a shaped current conductor (1) and a pulse current source (2) that is composed of a capacitor bank (3), a transfer switch (4) and a control unit (5). The compact set-up of the system is the prerequisite for a power circuit that has such a low resistance that the required high pulse currents are obtained at supply voltages of below 60 V. The transfer switch is an H bridge with four switches (7) that contain equal numbers of MOS transistors connected in parallel. The short pulse times that are achieved using the MOS transistors allow the use of shaped current conductors with which magnetized areas can be produced with a very high precision. The inventive system provides a means for saving components, electric power and time by a factor of up to 100.

Abstract: Energy exchanger valve (8) with thermostat valve (12), a housing (9) with inlet (20) and outlet (21), a thermostat bellows displaceable spindle (30) with seal (42) which, by the expansion/contraction of the thermostat bellows and against the pressure of a surrounding spring (31) can close/open an opening (27) with a seating (27a) in a transverse wall (24) between the inlet (20) and the outlet (21), and a piston (13) controlled by differential pressure for the control of a medium's differential pressure across a pre-setting (11) and a thermostat valve (12) consisting of the seating (27a) and the seal (42) between the inlet (20) and the piston (13), the thermostat valve (12) being able to cut off the flow between the inlet and the outlet independently of the pre-setting (11). With the valve (8), only a predetermined maximum amount of the energy-carrying medium flows through the energy exchangers (5).

Abstract: Energy exchanger, valve (8) with thermostat valve (12), a housing (9) with inlet (15) and outlet (16), a thermostat bellows displaceable spindle (42) with a seal (32) which, against the pressure of a spring (43) surrounding the spindle (42), closes/opens an opening (28) in a transverse wall (29) in the housing (9) between the inlet (15) and the outlet (16), and a membrane (17, 21) controlled by the differential pressure for the control of an energy-carrying medium between the inlet (15) and the outlet (16), and an adjustable closing element (11) between the inlet (15) and the membrane (17, 21), the thermostat valve (12) being able to shut off the flow between the inlet (15) and the outlet (16) independently of the closing element (11). With the valve (8), only a predetermined maximum amount of the medium flows through the energy exchangers (5). If the differential pressure increases upon the closing of one or more valves on a pipe length, the flow in the individual energy exchanger (5) is not increased.